One drug carries the whole story as options narrow
- Immunovant has no approved products and has not generated revenue to date.
- After two Phase 3 failures in thyroid eye disease, the company stopped all batoclimab development.
- The company is a pure bet on IMVT-1402, but the program recently dropped Sjögren's disease and failed in cutaneous lupus.
- Strong data in rheumatoid arthritis validated the drug mechanism, showing deep IgG suppression works for patients.
- Cash and cash equivalents were $902.1 million at March 31, 2026, which management says can fund work through a possible first launch.
A cleaner but riskier bet
Immunovant used to have two active drugs in the story. That changed in April 2026 when batoclimab failed two Phase 3 studies in thyroid eye disease. The company stopped all batoclimab development as a result. Now, the pipeline is narrowing further. Management announced in November 2026 that IMVT-1402 failed its trial in cutaneous lupus and that the company will likely drop its Sjögren's disease program.
The bull case relies entirely on IMVT-1402 succeeding in its remaining targets. This drug is designed to lower harmful IgG antibodies with less effect on albumin and LDL cholesterol. In late 2026, the drug showed strong response rates in a rheumatoid arthritis trial. A 600mg dose maintained a response for 92.5 percent of patients compared to about 75 percent for placebo. This gave the company strong proof that IMVT-1402 works in patients who need deep antibody suppression.
The bear case is simple. One drug carries all of the company value, and the list of diseases it can treat is getting shorter. A clinical delay, safety problem, or regulatory rejection would hurt the whole thesis at once.
The balance sheet gives the company room to try. Management has stated that existing cash can fund announced programs through a possible first commercial launch of IMVT-1402 in Graves' Disease. That lowers near-term financing risk, but clinical risk remains high.
No sales until approval
Immunovant is a pre-revenue biotech. It does not sell any medicine today. Its value depends on running clinical trials, getting regulators to approve IMVT-1402, and then selling or partnering the drug.
The company funds itself through stock offerings instead of product cash flow. That is common for clinical-stage biotech, but it means shareholders face dilution if trials take longer or cost more than planned.
The possible moat is the drug profile and the patents around it. IMVT-1402 is given under the skin and targets FcRn, a receptor that helps IgG antibodies stay in the body. Blocking FcRn can lower IgG, which may help diseases where IgG antibodies attack healthy tissue.
The model breaks easily. If IMVT-1402 cannot show strong benefit and clean safety in late-stage trials, there is no second active drug program to rely on.
IMVT-1402 takes center stage
IMVT-1402 in Graves' Disease
This is the lead commercial target. Immunovant expects top-line results from the IMVT-1402 Graves' Disease trials in 2027.
IMVT-1402 in difficult-to-treat rheumatoid arthritis
This program showed positive Phase 2 maintenance data in late 2026. The company expects FDA feedback on a Phase 3 trial design soon.
IMVT-1402 in myasthenia gravis
Myasthenia gravis is already a proven anti-FcRn market for other companies. Immunovant expects IMVT-1402 top-line results in MG in 2027.
IMVT-1402 in chronic inflammatory demyelinating polyneuropathy
CIDP is a nerve disease where lowering harmful antibodies may help. Immunovant expects top-line results from this trial in 2028.
IMVT-1402 in Sjögren's disease
Management stated in November 2026 that the company will likely not progress this program based on updates in the field.
IMVT-1402 in cutaneous lupus erythematosus
This proof-of-concept trial failed in 2026 and did not succeed in showing the needed benefit.
Batoclimab
Batoclimab is no longer an active development program. Immunovant stopped all work on it after two Phase 3 thyroid eye disease studies missed their primary goals.
One research company
For fiscal 2026, Immunovant did not report revenue segments because it had no commercial products and had not generated revenue to date. The practical mix is all research and development activity.
What could break the thesis
Single-asset dependence
High impact · Medium oddsImmunovant is tied entirely to IMVT-1402. That focus can help execution, but it also means a bad safety signal or weak efficacy result would damage the whole company. Recent failures in lupus and Sjögren's show the drug will not work everywhere.
HanAll partnership dispute
Medium impact · Medium oddsImmunovant licenses key assets from HanAll. Following the stop of batoclimab, HanAll may disagree with Immunovant's actions. The matter could lead to arbitration or litigation, creating cost, delay, or distraction.
Manufacturing and BIOSECURE Act risk
Medium impact · Medium oddsThe BIOSECURE Act could restrict the use of some foreign contract manufacturers if they are named as biotechnology companies of concern. If any Immunovant supplier is affected, the company may need to move manufacturing, which is costly and slow.
FcRn competition
High impact · High oddsThe anti-FcRn field is crowded. Immunovant faces competitors like argenx, which has established strong class leadership in MG and CIDP. IMVT-1402 must show enough safety, efficacy, or convenience to win market share.
Future dilution
Medium impact · Low oddsManagement says current cash can fund announced programs through a possible first IMVT-1402 launch in Graves' Disease. Still, delays, extra trials, litigation, or manufacturing changes could force another equity raise.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Immunovant, Inc. in Finn's Biotechnology industry ranking.

